Symbiotec Pharmalab IPO Subscribes 80% on Day 1

Symbiotec Pharmalab’s Initial Public Offering recorded an 80% subscription rate on its opening day, August 24, 2026. Investors bid for 1,05,37,575 shares against 1,31,24,929 shares available.

IPO Details

• The bidding period runs from August 24 to August 27, 2026.
• The price band is set between Rs 938 and Rs 988 per equity share.
• Investors must bid for a minimum of 15 equity shares.

Offering Structure

The IPO includes a fresh issue and an offer for sale (OFS) component.

• Fresh Issue: Up to Rs 150 crore.
• Offer for Sale: Up to Rs 1,607 crore by Satwani Holdings LLP, Rosewood Investments, and India Business Excellence Fund III.
• Fresh issue funds will primarily repay Rs 112.5 crore in borrowings, with the remainder for general corporate purposes.

Anchor Investor Round

Ahead of the public offering, Symbiotec Pharmalab secured significant capital from anchor investors.

• Amount Raised: Rs 526.19 crore.
• Date: August 21, 2026.
• Investors: 34 anchor investors.
• Shares Allotted: 53.28 lakh shares at Rs 988 each.

Company Overview

Symbiotec Pharmalab operates in pharmaceuticals and biotechnology, with over three decades of experience. The company holds a strong global position in specific API segments.

• Specializations: Active Pharmaceutical Ingredients (APIs), Contract Development and Manufacturing Organization (CDMO) services, and complex injectables.
• Global Reach: Supplies over 60 APIs to more than 200 customers across 40+ countries.
• Backward Integration: Manufactures key starting materials for over 80% of its products by revenue.
• Expansion Areas: Biologics, GLP-1, insulin, niche APIs, and complex injectables.

Financial Snapshot

For the twelve-month period ending March 31, 2026, the company reported solid financial results.

• Consolidated Net Profit: Rs 109.88 crore.
• Sales: Rs 869.15 crore.

The strong subscription on the opening day indicates significant investor interest in Symbiotec Pharmalab’s market debut.